Seeking Alpha

Barron's questions relationship between Questcor, Chronic Disease Fund

  • Shares of Questcor Pharmaceuticals (QCOR) open lower by 2%.
  • Over the weekend, Barron's — long skeptical of QCOR — questioned the relationship between the company and the Chronic Disease Fund.
  • Bill Alpert asks whether the the two are "too close for comfort" and says the charity's help with co-pays is a major reason QCOR has been able to help patients obtain Acthar.
  • "The co-pay arrangement with the CDF carries its own risk," Alpert writes, adding that "eight of the 37 disease states for which the CDF Website says it is enrolling patients are diseases for which Acthar is the only drug on the charity's list of approved therapies—even though branded and generic alternatives for those diseases are on the market."
Comments (17)
  • trch3737
    , contributor
    Comments (15) | Send Message
     
    I think the writer is frantically supporting the short side!
    21 Oct 2013, 09:51 AM Reply Like
  • ksu
    , contributor
    Comments (64) | Send Message
     
    Is it illegal for QCOR to do so? If not, what is the question? If yes, should take it to the court instead of to the market. Only purpose is to support the short side.
    21 Oct 2013, 10:02 AM Reply Like
  • Hoang6
    , contributor
    Comments (254) | Send Message
     
    I rode QCOR from $20 to $75 lately thanks to this kind of question. Beat it!
    21 Oct 2013, 11:53 AM Reply Like
  • Human Terrain Guy
    , contributor
    Comments (6) | Send Message
     
    I hope it does go down to the $50's, I need to buy some more.
    21 Oct 2013, 11:54 AM Reply Like
  • PeterScriabin
    , contributor
    Comments (220) | Send Message
     
    The Barrons writer stated that WS short-sellers who tried to crash the CDF event showed him letters from Questcor (1) denying admission to the event (2) threatening legal action.

     

    One wonders just who these short-sellers might be? Hmm, pity SA felt it had to suppress Michael Fuller's writings, which bore mightily on that topic.

     

    Here's part of a comment on the Barrons article:

     

    "Looking at CDF website there are many well known drugs that they cover. H-P Achtar is one of over 70 drugs covered.

     

    The company has been the target of short sellers, and this article is another attempt to bring down the stock price.

     

    The mechanism of action of H-P Achtar is diff to those of steroids, so prednisone is a poor comparison. One of Achtar's mode of action is similar to that of prednisone but it acts through many other novel mechanisms which steroids do not. Furthermore, you have humiliated 1000s of doctors who prescribe Achtar: ie they don't know prednisone exists! Achtar is used after prednisone has failed! Then you have indirectly ridiculed the FDA:ie they approved the medication when steroids are an option! You're obviously hoping that readers of this article will be intellectually challenged and follow you through.......

     

    The entire article is suspect and I am ashamed to subscribe to Barrons. I had high regard for Barrons, despite misgivings of my colleagues. I will not give this article any more attention."
    21 Oct 2013, 11:56 AM Reply Like
  • ksu
    , contributor
    Comments (64) | Send Message
     
    I just throw Barron to recycle pin. I got it through mileage exchange and I'll never pay for it. Through my life in the market, Barron is one of the bad one to manipulate the stock price. It is usually to buy the stock they mentioned on Tuesday.
    21 Oct 2013, 01:09 PM Reply Like
  • mjtroll1
    , contributor
    Comments (1233) | Send Message
     
    excellent comment.. it does seem like barrons research pieces on shorts work fine for a "short" while.. but have trouble sustaining
    21 Oct 2013, 04:33 PM Reply Like
  • jonesey09
    , contributor
    Comment (1) | Send Message
     
    Wow......short much?
    21 Oct 2013, 11:56 AM Reply Like
  • 652448116
    , contributor
    Comment (1) | Send Message
     
    I have ms. Meds are 3 a-4k per month. As a result co pays are high . Drug companies and ms foundations have long offered help with co -pays . This is even more true now that more therapies are available. I don't understand Barron's problem with qcor especially since steroids are cheap and have horrific side effects. Patients with diseases where steroids are the only treatment option often die from the side effects before the actual disease kills them.
    21 Oct 2013, 12:54 PM Reply Like
  • jerry parker
    , contributor
    Comments (81) | Send Message
     
    the boy who cried wolf cried, again...and we all know what happened to people who make up lies, don't we?
    21 Oct 2013, 03:31 PM Reply Like
  • drdon
    , contributor
    Comments (201) | Send Message
     
    An obvious planned short maneuver aided and abetted by Barron's. These are all of the Wall St. whores who will stop at nothing to achieve their goals. They have tried and short term have knocked the stock down, in the past (look where it advanced to since) but this time the down action has been limited and the pps is moving back up. These unscrupulous individuals and funds care not a whit that Acthar has been of inestimable value to a segment of acutely ill individuals. Profit at any cost is their motto. Barron's shows itself as a real hack publication. Oh by the way earnings next week. Care to guess what they will be and where the pps will be?
    21 Oct 2013, 03:52 PM Reply Like
  • mjtroll1
    , contributor
    Comments (1233) | Send Message
     
    excellent comments..I emailed company and asked them if/when they plan a press release to discuss allegations..have not heard back.. also regarding barron;s as source for shorts.. I have had "mixed success"... their research definitely helps if you already have a position
    21 Oct 2013, 04:33 PM Reply Like
  • Hoang6
    , contributor
    Comments (254) | Send Message
     
    The nose dive must be caused by institutional manipulations, what really amused me was that they sold the stocks based on an article published on Barron's. Aren't they supposed to have their own analysts to do their own researches? Crazy reactions simply based on what other people said? Just wow!
    21 Oct 2013, 07:10 PM Reply Like
  • danjong9
    , contributor
    Comments (9) | Send Message
     
    read more about "ready to be bought by big pharma" on BARRON
    weekend story. be happy to all.
    21 Oct 2013, 10:00 PM Reply Like
  • danjong9
    , contributor
    Comments (9) | Send Message
     
    Barron is helper or short seller?
    21 Oct 2013, 10:06 PM Reply Like
  • danjong9
    , contributor
    Comments (9) | Send Message
     
    Did you read "qcor is ready to be bought by Big pharma" on Barron?
    21 Oct 2013, 10:14 PM Reply Like
  • danjong9
    , contributor
    Comments (9) | Send Message
     
    we misunderstand whatever is, it is not Barron's question relationship between....I think it is their business. they just do not want anybody know their own on going business. if you are one of them, I am sure you will be just like them. good or bad does not matter.
    I am sure they are doing good business for their company To me they take care their business very well. just wait...
    We will see all soon.
    22 Oct 2013, 02:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector